Rheumatology Medical News about Chronic fatigue syndrome, Infectious Mononucleosis, Adolescents

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chronic fatigue syndrome after infectious mononucleosis in adolescents
Pediatrics, 07/13/09

Katz BZ et al. – Study reports that the infectious mononucleosis may be a risk factor for chronic fatigue syndrome in adolescents. Female gender and greater fatigue severity, but not reported steroid use during the acute illness, were associated with this syndrome.

Methods

Goal was to characterize prospectively the course and outcome of chronic fatigue syndrome in adolescents during a 2-yr period after infectious mononucleosis
301 adolescents (12–18 yrs), screened for nonrecovery 6 mo after infectious mononucleosis by telephone screening interview
Nonrecovered adolescents underwent a medical evaluation, with f/u screening 12 and 24 mo after infectious mononucleosis
After blind review, final diagnoses of chronic fatigue syndrome at 6, 12, and 24 mo were made by using established pediatric criteria

Results

6, 12, and 24 mo after infectious mononucleosis, 13%, 7%, and 4% of adolescents, respectively, met the criteria
Most individuals recovered with time
Only 2 adolescents at 24 mo seemed to have recovered or had an explanation for chronic fatigue at 12 mo but then were reclassified as having syndrome at 24 mo
All 13 adolescents 24 mo after infectious mononucleosis were female and, on average, reported greater fatigue severity at 12 mo
Reported use of steroid therapy during the acute phase of infectious mononucleosis did not increase the risk of developing the syndrome

<< Previous
Milnacipran: A serotonin and norepinephrine reuptake inhibitor...

Next >>
Wnt and PPAR-γ signaling in osteoblastogenesis and...